Evidence map›Paper›PMID 37604658›Full record

ReviewNeurology2023

Beyond the Guidelines: A Narrative Review of Treatments on the Horizon for Migraine in Children and Adolescents.

Juliana H VanderPluym, M Cristina C Victorio, Christopher B Oakley, Reena G Rastogi, Serena L Orr

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Juliana H VanderPluymFrom the Department of Neurology (J.H.V.), Mayo Clinic, Scottsdale, AZ; Division of Neurology (M.C.C.V.), NeuroDevelopmental Science Center, Akron Children's Hospital, OH; Department of Neurology (C.B.O.), Johns Hopkins University School of Medicine, Baltimore, MD; Division of Neurology (R.G.R.), Barrow Neurological Institute at Phoenix Children's Hospital, AZ; Department of Child Health and Neurology (R.G.R.), University of Arizona College of Medicine-Phoenix; Departments of Pediatrics (S.L.O.), Community Health Sciences, and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Alberta; and Department of Neurology (S.L.O.), Alberta Children's Hospital, Calgary, Canada. vanderpluym.juliana@mayo.edu.
M Cristina C VictorioFrom the Department of Neurology (J.H.V.), Mayo Clinic, Scottsdale, AZ; Division of Neurology (M.C.C.V.), NeuroDevelopmental Science Center, Akron Children's Hospital, OH; Department of Neurology (C.B.O.), Johns Hopkins University School of Medicine, Baltimore, MD; Division of Neurology (R.G.R.), Barrow Neurological Institute at Phoenix Children's Hospital, AZ; Department of Child Health and Neurology (R.G.R.), University of Arizona College of Medicine-Phoenix; Departments of Pediatrics (S.L.O.), Community Health Sciences, and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Alberta; and Department of Neurology (S.L.O.), Alberta Children's Hospital, Calgary, Canada.
Christopher B OakleyFrom the Department of Neurology (J.H.V.), Mayo Clinic, Scottsdale, AZ; Division of Neurology (M.C.C.V.), NeuroDevelopmental Science Center, Akron Children's Hospital, OH; Department of Neurology (C.B.O.), Johns Hopkins University School of Medicine, Baltimore, MD; Division of Neurology (R.G.R.), Barrow Neurological Institute at Phoenix Children's Hospital, AZ; Department of Child Health and Neurology (R.G.R.), University of Arizona College of Medicine-Phoenix; Departments of Pediatrics (S.L.O.), Community Health Sciences, and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Alberta; and Department of Neurology (S.L.O.), Alberta Children's Hospital, Calgary, Canada.
Reena G RastogiFrom the Department of Neurology (J.H.V.), Mayo Clinic, Scottsdale, AZ; Division of Neurology (M.C.C.V.), NeuroDevelopmental Science Center, Akron Children's Hospital, OH; Department of Neurology (C.B.O.), Johns Hopkins University School of Medicine, Baltimore, MD; Division of Neurology (R.G.R.), Barrow Neurological Institute at Phoenix Children's Hospital, AZ; Department of Child Health and Neurology (R.G.R.), University of Arizona College of Medicine-Phoenix; Departments of Pediatrics (S.L.O.), Community Health Sciences, and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Alberta; and Department of Neurology (S.L.O.), Alberta Children's Hospital, Calgary, Canada.
Serena L OrrFrom the Department of Neurology (J.H.V.), Mayo Clinic, Scottsdale, AZ; Division of Neurology (M.C.C.V.), NeuroDevelopmental Science Center, Akron Children's Hospital, OH; Department of Neurology (C.B.O.), Johns Hopkins University School of Medicine, Baltimore, MD; Division of Neurology (R.G.R.), Barrow Neurological Institute at Phoenix Children's Hospital, AZ; Department of Child Health and Neurology (R.G.R.), University of Arizona College of Medicine-Phoenix; Departments of Pediatrics (S.L.O.), Community Health Sciences, and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Alberta; and Department of Neurology (S.L.O.), Alberta Children's Hospital, Calgary, Canada.ORCID 0000-0002-2879-811X
Barrow Neurological Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is common in children and adolescents and can cause significant disability. There are relatively limited evidence-based treatment options available, especially when compared with treatment of migraine in adults. The Pediatric Research Equity Act requires the study of a new drug or biologic in pediatric populations. As such it is mandatory that the newest migraine treatment options available for adults be evaluated in children and adolescents. It will take years before results from clinical trials in pediatric patients become available. In the meantime, there is eagerness among clinicians to seek out the existing evidence that may help provide clarity on utilization of the newer migraine therapies in children and adolescents because many of the currently available, guideline-recommended treatments do not provide benefit for all patients. In this narrative review, the literature regarding onabotulinumtoxinA, neuromodulatory devices, calcitonin gene-related peptide (CGRP) monoclonal antibodies, 5-hydroxytryptamine (1F) agonists (i.e., ditans), and CGRP small-molecule receptor antagonists (i.e., gepants) for the treatment of migraine in children and adolescents will be summarized.

Indexed as

Calcitonin Gene-Related PeptideMigraine DisordersAdolescentAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor AntagonistsChildHumansReceptors, Calcitonin Gene-Related PeptideAntibodies, MonoclonalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsReceptors, Calcitonin Gene-Related Peptide

Identifiers

PMID37604658
PMCPMC10634646
OpenAlexW4386033540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.